Drug intelligence / Profile preview

VRC01

Development stage: Phase 2
Lead developer: National Institutes of Health
Modality: Anti-infectious Disease mAbs → Neutralizing Antibodies → Monoclonal Antibodies → Antibody-Based Therapeutics, Naked Antibodies → Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous, Subcutaneous

Overview

VRC01 is an investigational broadly neutralizing HIV-1 monoclonal antibody (bNAb) isolated from the B cells of an HIV-infected patient. It is directed against the HIV-1 CD4 binding site and is capable of potently neutralizing the majority of diverse HIV-1 strains. VRC01 works by binding to the conserved CD4-binding site on HIV-1 Env, preventing viral entry into target cells. It has been studied for both HIV treatment and prevention.

Other names: VRC01LSVRC-01LSVRC 01LS

Targets

Env (HIV-1 envelope glycoprotein)

Beyond the preview

Go deeper on VRC01.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VRC01.

Explore the full profile